Literature DB >> 2207343

Hyperviscosity in HIV infected children--a potential hazard during intravenous immunoglobulin therapy.

R A Hague1, O B Eden, P L Yap, J Y Mok, P Rae.   

Abstract

A four year old boy with symptoms of HIV infection and serum IgG of 53.2 g/l had been treated for 16 months with regular infusions of intravenous immunoglobulin (IV IgG). During one such infusion he developed temporary neurological symptoms and signs suggestive of the hyperviscosity syndrome. Serum relative viscosity was raised at 5.0 (normal range 0.42-2.78). Subsequent IV IgG infusions given at a slower rate have been without adverse reactions. In a study of eight HIV infected children including the index case, and 20 children not infected with HIV, serum relative viscosity was significantly raised in the HIV infected children (p less than 0.01; students t-test). Viscosity correlated with total serum IgG, which was raised in all HIV infected children, and with serum IgM. In HIV infected children with very high levels of serum IgG a slow rate of IV IgG infusion should therefore be chosen due to the possibility of hyperviscosity.

Entities:  

Mesh:

Substances:

Year:  1990        PMID: 2207343     DOI: 10.1007/bf02076702

Source DB:  PubMed          Journal:  Blut        ISSN: 0006-5242


  11 in total

1.  SERUM HYPERVISCOSITY SYNDROME.

Authors:  J L FAHEY; W F BARTH; A SOLOMON
Journal:  JAMA       Date:  1965-05-10       Impact factor: 56.272

2.  Intravenous gamma-globulin in infant acquired immunodeficiency syndrome.

Authors:  T A Calvelli; A Rubinstein
Journal:  Pediatr Infect Dis       Date:  1986 May-Jun

3.  Pediatric acquired immunodeficiency syndrome. Neurologic syndromes.

Authors:  A L Belman; G Diamond; D Dickson; D Horoupian; J Llena; G Lantos; A Rubinstein
Journal:  Am J Dis Child       Date:  1988-01

Review 4.  Rheology of paraproteinaemias and the plasma hyperviscosity syndrome.

Authors:  T Somer
Journal:  Baillieres Clin Haematol       Date:  1987-09

Review 5.  Immune complex mediated rheumatic diseases.

Authors:  T Somer; D J Wallace; P T Fan
Journal:  Ann Clin Res       Date:  1980-04

6.  Hyperviscosity syndrome in a patient with acquired immunodeficiency syndrome.

Authors:  C M Martin; A G Matlow; E Chew; D Sutton; W Pruzanski
Journal:  Arch Intern Med       Date:  1989-06

7.  The management of children born to human immunodeficiency virus seropositive women.

Authors:  J Y Mok; R A Hague; R F Taylor; R P Brettle; F D Hargreaves; J M Inglis; P L Yap
Journal:  J Infect       Date:  1989-03       Impact factor: 6.072

8.  Increase of serum immunoglobulin level into the normal range in primary hypogammaglobulinaemia by dosage individualization of intravenous immunoglobulin.

Authors:  C L Leen; P L Yap; D B McClelland
Journal:  Vox Sang       Date:  1986       Impact factor: 2.144

9.  Intravenous immune globulin in symptomatic paediatric human immunodeficiency virus infection.

Authors:  U B Schaad; A Gianella-Borradori; B Perret; P Imbach; A Morell
Journal:  Eur J Pediatr       Date:  1988-04       Impact factor: 3.183

10.  The acquired immunodeficiency syndrome in infants and children.

Authors:  A J Ammann
Journal:  Ann Intern Med       Date:  1985-11       Impact factor: 25.391

View more
  6 in total

Review 1.  Does intravenous immune globulin have a role in HIV-infected patients?

Authors:  P L Yap
Journal:  Clin Exp Immunol       Date:  1994-07       Impact factor: 4.330

2.  Combined therapy in human immunodeficiency virus-infected children--a 4-year experience.

Authors:  T Güngör; M Funk; R Linde; I Kynast; A Allendorf; C Lotz; S Ehrenforth; D Hofmann; B Kornhuber; W Kreuz
Journal:  Eur J Pediatr       Date:  1993-08       Impact factor: 3.183

3.  Efficacy of topical immunoglobulins against experimental adenoviral ocular infection.

Authors:  Edward C Nwanegbo; Eric G Romanowski; Y Jerold Gordon; Andrea Gambotto
Journal:  Invest Ophthalmol Vis Sci       Date:  2007-09       Impact factor: 4.799

Review 4.  Efficacy of Intravenous Immunoglobulin in Neurological Diseases.

Authors:  Jan D Lünemann; Isaak Quast; Marinos C Dalakas
Journal:  Neurotherapeutics       Date:  2016-01       Impact factor: 7.620

Review 5.  Adverse effects of intravenous immunoglobulin.

Authors:  S A Misbah; H M Chapel
Journal:  Drug Saf       Date:  1993-10       Impact factor: 5.606

Review 6.  Update on Intravenous Immunoglobulin in Neurology: Modulating Neuro-autoimmunity, Evolving Factors on Efficacy and Dosing and Challenges on Stopping Chronic IVIg Therapy.

Authors:  Marinos C Dalakas
Journal:  Neurotherapeutics       Date:  2021-11-11       Impact factor: 7.620

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.